Trillium Therapeutics (TRIL) Earning Somewhat Positive Media Coverage, Analysis Finds
News articles about Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Trillium Therapeutics earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.7743270508315 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
A number of research firms recently issued reports on TRIL. HC Wainwright set a $7.00 price target on shares of Trillium Therapeutics and gave the company a “buy” rating in a research note on Monday, August 14th. Zacks Investment Research downgraded shares of Trillium Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $18.00 price target on shares of Trillium Therapeutics in a research note on Friday, June 9th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Trillium Therapeutics in a research note on Wednesday, July 5th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $14.95.
Trillium Therapeutics (NASDAQ:TRIL) traded up 6.45% on Friday, reaching $4.95. 90,071 shares of the company’s stock were exchanged. Trillium Therapeutics has a one year low of $4.15 and a one year high of $17.70. The firm’s market cap is $53.43 million. The firm has a 50 day moving average price of $4.59 and a 200 day moving average price of $5.39.
TRADEMARK VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/09/01/trillium-therapeutics-tril-earning-somewhat-positive-media-coverage-analysis-finds.html.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
Receive News & Stock Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related stocks with our FREE daily email newsletter.